Study to Assess the Safety, Pharmacokinetics, and Pharmacodynamics of CHI-915 in Healthy Participants
NCT ID: NCT05210634
Last Updated: 2022-05-13
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
PHASE1
21 participants
INTERVENTIONAL
2022-01-11
2022-05-06
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study In Healthy People To Evaluate Safety, Toleration, Pharmacokinetics And Pharmacodynamics Of Multiple Oral Doses Of PF-06743649
NCT02151617
Safety and Tolerability of CFTX-1554 in Healthy Subjects
NCT05260658
A Study to Evaluate the Safety and Pharmacokinetics of CNTX-6016 in Healthy Subjects
NCT04154501
Evaluation Of Safety, Tolerability And Pharmacokinetics Of Single And Multiple Doses Of Compound PF-06823859
NCT02766621
A Phase I Trial to Investigate the Safety and Tolerability of PF-06649751
NCT01981694
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
CROSSOVER
OTHER
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Group 1: Placebo
Single oral administration of 4 ml of Placebo MCT oil
THCv
THCv in MCT oil
Group 2: 12.5 mg THCv (CHI-915)
Single oral administration of 12.5 mg THCv in MCT oil
THCv
THCv in MCT oil
Group 3: 25 mg THCv (CHI-915)
Single oral administration of 25 mg THCv in MCT oil
THCv
THCv in MCT oil
Group 4: 50 mg THCv (CHI-915)
Single oral administration of 50 mg THCv in MCT oil
THCv
THCv in MCT oil
Group 5: 100 mg THCv (CHI-915)
Single oral administration of 100 mg THCv in MCT oil
THCv
THCv in MCT oil
Group 6: 200 mg THCv (CHI-915)
Single oral administration of 200 mg THCv in MCT oil
THCv
THCv in MCT oil
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
THCv
THCv in MCT oil
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
2. Has a body mass index between 18 and 30 kg/m2.
3. Is judged by the Investigator to be in generally good health at screening based on the results of a medical history, physical examination, 12-lead ECG, and clinical laboratory test results. Laboratory results outside of the reference range deemed to be acceptable will be documented as not clinically significant at the discretion of the Investigator.
4. For women of childbearing potential, has a negative serum pregnancy test (β-human chorionic gonadotropin \[hCG\]) at the Screening Visit and a negative urine pregnancy test at intake to the research facility.
5. Must be adequately informed of the nature and risks of the study and give written informed consent prior to screening.
6. Is, in the Investigator's opinion, reliable, able, and willing to comply with all protocol requirements and procedures (including scheduled visits).
Exclusion Criteria
2. Women of childbearing potential, or men who are sexually active with a woman of childbearing potential, who are unwilling or unable to use an acceptable method of contraception (abstinence or the use of a highly effective method of contraception, including hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom, vasectomy, or intrauterine device) from at least 21 days prior to the first dose of study medication until 28 days after the last dose of study medication. Participants with same sex partners or who maintain abstinence do not require contraception.
3. Person has history of diagnosis related to hepatic function and/or significantly impaired hepatic function (alanine aminotransferase \[ALT\] \>3x upper limit of normal \[ULN\] or total bilirubin \[TBL\] \>2 x ULN) OR the ALT or aspartate aminotransferase (AST) \>2 x ULN and TBL \>2 x ULN (or international normalized ratio \[INR\] \>1.5).
4. Has a history of epilepsy.
5. Has used tobacco/nicotine-containing products on more than 10 occasions within 30 days of dosing with study IP or during the study.
6. Has used any prescription drugs or herbal supplements (except hormonal contraception) within 30 days prior to receiving the first dose of IP, unless approved by the Investigator and stable for at least 30 days prior to the first dose of IP through the final study visit.
7. Use of any over-the-counter drugs, vitamins, or supplements within 24 hours prior to dosing with the IP.
8. Has or has previously had a positive result for the presence of Hepatitis B surface antigen (HBsAg), Hepatitis C virus antibodies (HCVAb), or human immunodeficiency virus (HIV) antibodies.
9. Has a positive breath, urine, or serum test for ethanol or a positive urine screen for cocaine, THC, barbiturates, amphetamines, methamphetamines, benzodiazepines, methylenedioxymethamphetamine, phencyclidine, methadone, or opiates at the Screening Visit or prior to IP administration.
10. Any clinically significant condition or abnormal finding at the Screening Visit that would, in the opinion of the Investigator, preclude study participation or interfere with evaluation of the IP.
11. Has a history of a known significant allergic condition, significant drug-related hypersensitivity, or allergic reaction to any compound or chemical class related to cannabis, including phytocannabinoids and cannabinoid analogues, or excipients utilized within the IP.
12. Has taken grapefruit products and/or Seville oranges within the 7 days prior to dosing with study medication or during the study.
13. Is taking a prohibited medication or supplement including warfarin, clobazam, valproic acid, phenobarbital, mTOR inhibitors, oral tacrolimus, and St. John's Wort within 30 days prior to receiving the first dose of IP or during the study.
14. Has used cannabis, synthetic cannabinoid, or cannabinoid analogues (e.g., dronabinol, nabilone), hemp products, synthetic cannabinoid receptor agonists (e.g., spice, K2), or any cannabidiol (CBD) or THC-containing product (e.g., Sativex, Epidiolex) within 4 weeks of the Screening Visit or during the study and has used cannabis on more than 25 occasions in the last 12 months.
15. Meets criteria for past-year Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5)-defined psychiatric disorder, or moderate to severe substance use disorder.
16. Has a lifetime history of psychosis or schizophrenia or a first-degree relative experiencing psychosis or schizophrenia.
17. Endorses current suicidal intent as indexed by endorsement of questions #4 or #5 on the Columbia-Suicide Severity Rating Scale (C-SSRS).
18. Has suspected or confirmed cardiovascular disease.
19. Has participated in any investigational product or device study within 30 days prior to receiving the first dose of IP or is scheduled to participate in another investigational product or device study during the course of this study.
20. Demonstrates behavior indicating unreliability or inability to comply with the requirements of the protocol.
18 Years
55 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Canopy Growth Corporation
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Nucleus Network
Saint Paul, Minnesota, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Sempio C, Campos-Palomino J, Klawitter J, Peters EN, MacNair L, Haghdoost M, Bonn-Miller MO, Harrison A, Babalonis S, Christians U, Klawitter J. Pharmacokinetics of Oral Cannabinoid Delta8-Tetrahydrocannabivarin and Its Main Metabolites in Healthy Participants. Pharmaceuticals (Basel). 2024 Nov 27;17(12):1603. doi: 10.3390/ph17121603.
Peters EN, MacNair L, Harrison A, Feldner MT, Eglit GML, Babalonis S, Turcotte C, Bonn-Miller MO. A Two-Phase, Dose-Ranging, Placebo-Controlled Study of the Safety and Preliminary Test of Acute Effects of Oral Delta8-Tetrahydrocannabivarin in Healthy Participants. Cannabis Cannabinoid Res. 2023 Sep;8(S1):S71-S82. doi: 10.1089/can.2023.0038.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
710022US1312
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.